Development of retroviral‐based gene therapy products: a quality control perspective
This early article provided a broad overview and a brief history of quality control considerations in the development of retroviral-based gene therapy products. As part of pioneering efforts in the field and early regulatory experience, I was invited to contribute this article as a guidance to others.
